The problem, Braunwald notes, is that "minimal exertion" can mean different things to different people.

FORBES: Johnson & Johnson Lost A Blockbuster

"I think there is significant work that has to be done, " says Braunwald.

FORBES: Johnson & Johnson Lost A Blockbuster

Improve It is being conducted by some top researchers, including Harvard University's Eugene Braunwald and Duke University's Robert Califf .

FORBES: Merck, Schering Launch Huge Heart-Drug Test

"Overall, I'm very pleased with the fact that intense cholesterol lowering reduces coronary events in patients with aortic stenosis, " said Braunwald.

FORBES: Another Blow For Merck And Schering

Braunwald's panel recommended that use of Natrecor be limited to a more restricted population than that for which the drug is approved.

FORBES: Bitter Pill For J&J On Heart Drug

The drug giant convened the ten-member panel, headed by Eugene Braunwald of Harvard Medical School in Boston, to examine the safety of heart-failure treatment Natrecor.

FORBES: Magazine Article

Eugene Braunwald, a prominent Harvard cardiologist who is running a Vytorin trial, called Peto "the best statistician in the universe" while telling reporters that any cancer risk with the drug is unlikely.

FORBES: Magazine Article

Eugene Braunwald of Harvard University, who chaired the panel, and Wilson S. Colucci of Boston University, who served on it, say they would support tightening the FDA's labeling of Natrecor to prevent injudicious use of the drug.

FORBES: Cardiologist Calls For Limits On J&J Drug

"This raises the bar, " says Braunwald.

FORBES: Johnson & Johnson Lost A Blockbuster

Harvard's Eugene Braunwald, one of the most well regarded cardiologists in the country, said that an analysis of the data hadn't given a safety committee reason to stop a large study of Vytorin and Zocor that he is running, called IMPROVE-IT.

FORBES: Another Blow For Merck And Schering